A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer

被引：116

作者：

Qu, Xinhua ^{[1
,2
]}

Huang, Xiaolu ^{[3
]}

Yan, Weili ^{[4
]}

Wu, Lianming ^{[5
]}

Dai, Kerong ^{[1
,2
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Key Lab Orthopaed Implant, Dept Orthopaed, Sch Med,Shanghai Peoples Hosp 9, Shanghai 200011, Peoples R China

[2] PRC, Minist Educ, Engn Res Ctr Digital Med, Shanghai 200030, Peoples R China

[3] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Plast & Reconstruct Surg, Shanghai 200011, Peoples R China

[4] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Nucl Med, Shanghai 200127, Peoples R China

[5] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Radiol, Shanghai 200127, Peoples R China

来源：

EUROPEAN JOURNAL OF RADIOLOGY | 2012年 / 81卷 / 05期

关键词：

Lung cancer; Bone metastasis; Positron emission tomography with computed tomography; Positron emission tomography; Magnetic resonance imaging; Bone scintigraphy; Meta-analysis; POSITRON-EMISSION-TOMOGRAPHY; BODY FDG-PET/CT; FOLLOW-UP; ACCURACY; PERFORMANCE; GUIDELINES; MARKERS; SCAN; CT;

D O I：

10.1016/j.ejrad.2011.01.126

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Background and purpose: Lung cancer is the most common cause of cancer related death among both men and women worldwide. The skeleton is the most common site of cancer metastasis. Early detection is crucial for prognosis. To evaluate and compare the capability for bone metastasis assessment of [F-18] fluoro-2-d-glucose positron emission tomography with computed tomography ((18)FDG-PET-CT), [F-18] fluoro-2-d-glucose positron emission tomography ((18)FDG-PET), magnetic resonance imaging (MRI) and bone scintigraphy (BS) in lung cancer patients, a meta-analysis is preformed. Methods: We searched MEDLINE, OVID, EMBASE and the Cochrane Library for studies evaluating diagnosis validity of (18)FDG-PET-CT, (18)FDG-PET, MRI and BS between January 1990 and August 2010. Meta-analysis methods were used to pool sensitivity, specificity, diagnostic odd ratios (DORs) and to construct a summary receiver-operating characteristic curve (SROC). Results: A total of 17 articles (9 (18)FDG-PET-CT studies, 9 (18)FDG-PET studies, 6 MRI studies and 16 BS studies) that included 2940 patients who fulfilled all of the inclusion criteria were considered for inclusion in the analysis. The pooled sensitivity for the detection of bone metastasis in lung cancer using (18)FDG-PET- CT, (18)FDG-PET, MRI and BS were 0.92 (95% CI, 0.88-0.95), 0.87 (95% CI, 0.81-0.92), 0.77 (95% CI, 0.65-0.87) and 0.86 (95% CI, 0.82-0.89), respectively. The pooled specificity for the detection of bone metastasis from lung cancer using (18)FDG-PET-CT, (18)FDG-PET, MRI and BS were 0.98 (95% CI, 0.97-0.98), 0.94 (95% CI, 0.92-0.96), 0.92 (95% CI, 0.88-0.95), 0.88 (95% CI, 0.86-0.89), respectively. The pooled DORs estimates for (18)FDG-PET-CT 449.17 were significantly higher than for (18)FDG-PET (118.25, P < 0.001), MRI (38.27, P < 0.001) and BS (63.37, P < 0.001). The pooled sensitivity of BS was not correlated with the prevalence of bone metastasis. Conclusion: The results showed that both (18)FDG-PET-CT and (18)FDG-PET were better imaging methods for diagnosing bone metastasis from lung cancer than MRI and BS. (18)FDG-PET-CT has higher diagnostic value (sensitivity, specificity and DORs) for diagnosing bone metastasis from lung cancer than any other imaging methods. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1007 / 1015

页数：9

共 33 条

[1] Does blinding of readers affect the results of meta-analyses? [J].

Berlin, JA .

LANCET, 1997, 350 (9072) :185-186

[2] The STARD statement for reporting studies of diagnostic accuracy: Explanation and elaboration [J].

Bossuyt, PM ;

Reitsma, JB ;

Bruns, DE ;

Gatsonis, CA ;

Glasziou, PP ;

Irwig, LM ;

Moher, D ;

Rennie, D ;

de Vet, HCW ;

Lijmer, JG .

CLINICAL CHEMISTRY, 2003, 49 (01) :7-18

[3] Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors [J].

Brown, JE ;

Cook, RJ ;

Major, P ;

Lipton, A ;

Saad, F ;

Smith, M ;

Lee, KA ;

Zheng, M ;

Hei, YJ ;

Coleman, RE .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01) :59-69

[4] Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer [J].

Bury, T ;

Barreto, A ;

Daenen, F ;

Barthelemy, N ;

Ghaye, B ;

Rigo, P .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (09) :1244-1247

[5] Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer [J].

Cheran, SK ;

Herndon, JE ;

Patz, EF .

LUNG CANCER, 2004, 44 (03) :317-325

[6] Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

D'Addario, G. ;

Frueh, M. ;

Reck, M. ;

Baumann, P. ;

Klepetko, W. ;

Felip, E. .

ANNALS OF ONCOLOGY, 2010, 21 :v116-v119

[7] The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed [J].

Deeks, JJ ;

Macaskill, P ;

Irwig, L .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 2005, 58 (09) :882-893

[8] Suspected non-small cell lung cancer: Incidence of occult brain and skeletal metastases and effectiveness of imaging for detection - Pilot study [J].

Earnest, F ;

Ryu, JH ;

Miller, GM ;

Luetmer, PH ;

Forstrom, LA ;

Burnett, OL ;

Rowland, CM ;

Swensen, SJ ;

Midthun, DE .

RADIOLOGY, 1999, 211 (01) :137-145

[9]

Ebert W, 2004, ANTICANCER RES, V24, P3193

[10] The role of whole-body bone scanning and clinical factors in detecting bone metastases in patients with non-small cell lung cancer [J].

Erturan, S ;

Yaman, M ;

Aydin, G ;

Uzel, I ;

Müsellim, B ;

Kaynak, K .

CHEST, 2005, 127 (02) :449-454

← 1 2 3 4 →